FDA Panel Backs GRAIL's Galleri Multi-Cancer Early Detection Test; GRAL Shares in Focus

An FDA advisory panel voted in favor of GRAIL Inc.'s Galleri multi-cancer early detection test on September 23, 2026, moving the blood-based screening product one step closer to regulatory approval. The favorable recommendation is non-binding, but the FDA typically follows panel guidance when deciding on clearance. GRAIL, a subsidiary of Illumina (ILMN), trades under the ticker GRAL. Galleri is designed to screen for multiple cancer types from a single blood draw. An affirmative FDA decision would open a significant commercial market for the company.